论文部分内容阅读
会议及AHA的刊物JAMA同时介绍了一个备受关注的临床试验PREVENT-Ⅳ,该试验研究了E2F转录因子的双链低聚核苷酸假性诱物 edifoligide。据认为,E2F转录因子上调了参与新生内膜增生的关键性基因。美国杜克大学John
Meeting and AHA Journal JAMA also introduced PREVENT-IV, a well-studied clinical trial investigating edifoligide, a double-stranded oligonucleotide pseudotype of the E2F transcription factor. It is thought that E2F transcription factor up-regulates the key genes involved in neointimal hyperplasia. John Duke University